Mercurity Fintech's 15min chart shows overbought RSI, narrowing Bollinger Bands.

According to Mercurity Fintech's 15-minute chart, the RSI has reached an overbought level and Bollinger Bands have narrowed significantly on October 16, 2025, at 16:00. This indicates that the stock price has risen rapidly and exceeds its fundamental support level. Furthermore, the magnitude of price fluctuations has decreased, suggesting that the stock price is experiencing a period of consolidation.

Pulmatrix Inc. (PULM), a clinical-stage biopharmaceutical company specializing in inhaled therapeutics, has seen its stock price experience significant volatility in recent weeks. According to Mercurity Fintech's 15-minute chart, the Relative Strength Index (RSI) has reached an overbought level, while the Bollinger Bands have narrowed significantly on October 16, 2025, at 16:00. These technical indicators suggest that the stock price has risen rapidly and may be overvalued, exceeding its fundamental support level.

The RSI, which typically ranges between 0 and 100, indicates that the stock has been overbought, with an RSI value above 70. This suggests that the stock price has risen too quickly and may be due for a correction. The narrowing of the Bollinger Bands indicates that the price volatility has decreased, suggesting a period of consolidation. This consolidation phase can be a sign that the stock is preparing for a potential reversal or a continuation of its current trend.

Pulmatrix has been focusing on cost-saving measures and exploring partnerships for its clinical assets, as evidenced by its recent financial results and corporate updates. The company has reported zero revenue in Q2 2025 and Q1 2025, with a net loss of $1.8M in Q1 2025 compared to a net income of $825K in Q1 2024. Despite these financial challenges, the company's cash position remains robust, with $5.8M as of June 30, 2025, expected to fund operations through the merger closing.

The company's merger with Cullgen, expected to close in June 2025, will create a Nasdaq-listed company focused on targeted protein degradation technology. This merger is a strategic move for Pulmatrix, aiming to leverage Cullgen's proprietary uSMITE™ platform and degrader-antibody conjugates (DACs) to advance its clinical programs. The merger is expected to provide Pulmatrix with additional funding and runway through 2026, with a combined cash position of approximately $65 million.

In conclusion, Pulmatrix's stock price has shown signs of overvaluation and consolidation, as indicated by the RSI and Bollinger Bands. While the company's financial performance has been challenging, the merger with Cullgen presents a strategic opportunity to advance its clinical programs and secure additional funding. Investors should closely monitor the company's progress and the potential impact of the merger on its stock price.